semaglutide 2 mg dose Ozempic® Pen Dosing Novo Nordisk's Ozempic® pill, the
Description
8 As a result, the remainder of this review focuses on GLP-1
Journal of Diabetes Research and Clinical Metabolism , 12(3), 150-159

Tirzepatide, a newer agent, received FDA approval in 2022 as Mounjaro for T2DM and was approved in 2023 for obesity [3]

GLP-1 Analogues Market Regional Analysis North America Holds the Largest Share in the GLP-1 Analogues Market North America dominates the GLP-1 analogues market with an estimated market share of over 76.05%, primarily driven by high obesity and diabetes prevalence, strong healthcare infrastructure, and early adoption of innovative therapies U.S
